Objective: Although type 2 diabetes is a strong risk factor for cardiovascular disease and mortality, information on its association with mortality and life expectancy according to cardiovascular comorbidities is limited, especially in Asia. Thus, this study assessed mortality and reductions in life expectancy associated with cardiometabolic multimorbidity.
on the association of diabetes and cardiovascular comorbidity with life expectancy is sparse, even in Western countries (5, 6) , and to our knowledge, none exists in Asia. For instance, a recent Korean study reported increased excess mortality in people with type 2 diabetes (10). However, besides mortality and excess mortality risks, the potential association of diabetes and cardiovascular comorbidity such as myocardial infarction (MI) and stroke with total life expectancy has not been investigated. Thus, despite the rapid increase in the prevalence of diabetes, currently, there are no Asian-specific estimates of life expectancy, to our knowledge, in people with diabetes and/or CVD.
Therefore, we aimed to estimate the life-years lost to type 2 diabetes according to the presence and type of cardiovascular comorbidity by using data from the Korean National Health Insurance Service-National Sample Cohort (NHIS-NSC).
Research Design and Methods

Study population
This study used data from the NHIS-NSC 2002-2013, details of which were described in previous studies (10) . The data are from a nationally representative random sample of 1,025,340 individuals, who account for ;2.2% of the entire population in 2002 (10) . The data were compiled by using probabilistic sampling to represent an individual's total annual medical expenses within each of 1,476 strata defined by age, sex, eligibility status (employed or self-employed), and income level (20 quantiles for each eligibility status and medical-aid beneficiary) combinations via proportional allocation from the 46,605,433 Korean residents in 2002 (10, 11) . The information included contains all inpatient and outpatient medical claims data, including personal information, prescription drugs, diagnostic and treatment codes, and primary and additional diagnosis codes. In addition, each unique deidentified number is linked to mortality information from the Korean National Statistical Office. Importantly, this cohort contains the general health examination data of subjects who participated in biannual examinations. From this cohort, retrospective data of individuals older than 30 years were extracted between January 2002 and December 2013 (N = 575,696). This study was approved by the NHIS inquiry commission. The personal privacy of each participant was protected by de-identification of the national insurance claim data for analysis. This study was also approved by the institutional review board of the Asan Medical Center (IRB-No 2016-0149).
Definition of type 2 diabetes
From the NHIS-NSC, we selected subjects with records of having type 2 diabetes between January 2002 and December 2006. Type 2 diabetes was defined if antidiabetic drugs were prescribed and the 10th revision of the International Classification of Diseases (ICD)-10 codes E11 (noninsulin-dependent diabetes mellitus), E12 (malnutrition-related diabetes mellitus), E13 (other specified diabetes mellitus), or E14 (unspecified diabetes mellitus) were assigned as either principal or additional diagnosis. Antidiabetic drugs dispensed in the pharmacy during the study period in Korea consisted of six classes (i.e., sulfonylureas, biguanide, a-glucosidase inhibitor, thiazolidinediones, meglitinide, and insulin) (12) . In addition, incretinbased therapies (i.e., glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) were not introduced within the study period.
Definition of cardiovascular comorbidity
MI and stroke (ischemic or hemorrhagic) were included as cardiovascular comorbidities in this study. Cases of MI and stroke that occurred between January 2002 and December 2006 were identified using hospital discharge records with the following ICD-10 codes as a principal or subsidiary diagnosis: codes for MI were I21 (ST elevation and non-ST elevation MI), I22 (subsequent ST elevation and non-ST elevation MI), I23 (certain current complications following ST elevation and non-ST elevation MI), whereas those of stroke included I63 (cerebral infarction), I64 (stroke, not specified as hemorrhage or infarction), I693 (sequelae of cerebral infarction), I694 (sequelae of stroke, not specified as hemorrhage or infarction), and G45 (transient cerebral ischemic attacks and related syndromes); I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I62 (other nontraumatic intracranial hemorrhage), I690 (sequelae of subarachnoid hemorrhage), I691 (sequelae of intracerebral hemorrhage), and I692 (sequelae of nontraumatic intracranial hemorrhage) (13).
This cohort was followed up from the index date until the end of the study period (i.e., December 31, 2013), until the last year of qualification for those who were alive, or until the date of death for those who died. We attempted to minimize the effect of existing medical conditions other than type 2 diabetes, stroke, and MI by excluding all deaths that occurred within the first year of the index date. In addition, we excluded those subjects with any history of admission due to malignancy based on ICD-10 code (C00 to C97) between January 2002 and December 2006, to avoid confounding the association between cardiovascular comorbidity and the risk of death due to preexisting malignancy (14) . Finally, subjects with a history of stroke and/or MI without diabetes were also excluded. The flow used to select study participants is summarized in Fig. 1 . 
Covariates
We included the following covariates based on ICD-10 code, which could have influence on mortality: hypertension (I10, essential hypertension), dyslipidemia (E78, disorders of lipoprotein metabolism and other lipidemias), and chronic kidney disease (N18-9, chronic kidney disease and unspecified kidney failure). As a separate analysis, we selected subjects who had undergone a health examinations between January 2002 and December 2006 (n =158,148; health examination cohort) among our whole cohort (Fig. 1) . In this subgroup, we considered the following additional covariates: body mass index (BMI; kg/m 2 ), smoking habits (current smoker vs noncurrent smoker), drinking habits (heavy drinking vs nonheavy drinking), and physical activity (moderate vs nonmoderate), defined as a frequency per week. Heavy drinking was defined as consuming seven or more drinks on the same occasion and more than 3 days per week, and moderate physical activity was defined as exercising at least five times per week.
Statistical analysis
We categorized participants into the following five mutually exclusive groups according to the presence and type of cardiometabolic morbidity at baseline: (1) none (reference group), (2) diabetes only, (3) diabetes and stroke, (4) diabetes and MI, and (5) diabetes, stroke, and MI. In addition, the latter three groups were described as having cardiometabolic multimorbidity, defined as a history of diabetes with at least one cardiovascular comorbidity. We assessed the associations of these baseline groups with the risk of death from any cause.
We calculated the mortality rate per 1000 person-years according to the disease status at baseline. Time to death was estimated by the Kaplan-Meier method and statistical differences among groups according to cardiometabolic morbidity were compared by the log-rank test. Next, hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression models. The HRs were obtained in our whole cohort and health examination cohort, in which other covariates including BMI, smoking and drinking habits, and physical activity could be obtained.
In addition, we estimated the life expectancies according to the age groups (5-year intervals from 30 years of age) and baseline cardiometabolic morbidities in our whole cohort. The detailed statistical methods used to estimate the life expectancies are described in the Supplemental Methods. After these estimations, we calculated the reductions in life expectancy according to the age groups and baseline cardiometabolic multimorbidity by adopting two different references: participants with none of the cardiometabolic conditions assessed in our cohort and general population data from the 2002 National Life Tables for Korea (15) . Finally, the age-specific contributions to differences in life expectancy due to cardiometabolic multimorbidity were estimated using Arriaga's decomposition methods (16) . The total contribution of an age group to the life expectancy gap (in years) is the sum of the direct, indirect, and interaction effects.
All statistical analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC).
Results
Baseline characteristics of the study subjects
Of the 569,831 participants, 40,026 (7.01%) had a history of diabetes at enrollment, 784 (0.14%) had a history of both diabetes and stroke, 326 (0.06%) had both diabetes and MI, and 25 (0.01%) had diabetes, stroke, and MI (Table 1 ). The NHIS database does not provide the exact age of each subject but instead indicates the ages ranges according to 18 age groups (infants younger than 1 year, ages 1 to 4 years, age groups with 5-year-intervals between 5 and 79 years, and $80 years) (9) . Although the number of enrolled subjects without cardiometabolic comorbidities declined with increasing age, it consistently peaked at 60 to 69 years of age among those with diabetes (29.19%), those with diabetes and stroke (38.01%), those with diabetes and MI (41.72%), and those with diabetes, MI, and stroke (36.00%; Table 1 ).
The most common comorbidity other than diabetes, MI, and stroke throughout all disease status categories was hypertension, followed by dyslipidemia and chronic kidney disease (Table 1 ). In participants with diabetes and those with diabetes and at least one of the cardiovascular comorbidities (i.e., MI and stroke), the prevalence of hypertension, dyslipidemia, and chronic kidney disease was significantly higher than that among those free of diabetes, MI, and stroke (Table 1) .
When other covariates were compared within the health examination cohort, participants with diabetes and/or cardiovascular comorbidities had higher systolic blood pressure, total cholesterol levels, and BMI, and a greater proportion of individuals with a moderate level of physical activity compared with participants free of diabetes, MI, and stroke (Table 1) .
Mortality among people with diabetes and without diabetes
In the reference group among our whole cohort, the all-cause mortality rate was 6.85 per 1000 person-years at risk (Table 2) . By contrast, the mortality rates were 19.86 per 1000 person-years in participants with a history of diabetes, 67.17 per 1000 person-years in those with diabetes and stroke, 66.34 per 1000 person-years in those with diabetes and MI, and 115.52 in those with diabetes, stroke, and MI (Table 2 ). When the mortality rate was calculated within the health examination cohort, a similar pattern was observed across these five groups (i.e., 4.02, 13.20, 41.06, 46.53, and 142.95, respectively, per 1000 person-years from the reference group to those with diabetes, stroke, and MI; Table 1 ). Figure 2 shows the survival curve according to the presence of cardiometabolic comorbidities in our whole cohort [ Fig. 2(a) ] and the heath examination cohort [ Fig.  2(b) ], respectively. Compared with reference group, the subjects of the other four groups (i.e., diabetes only, diabetes with stroke, diabetes with MI, and diabetes with MI and stroke) had higher probabilities of death (log-rank test, P , 0.001 for all comparisons). There was no statistical difference in the probabilities of death between subjects with diabetes and stroke vs those with diabetes and MI in both cohorts, and subjects with diabetes, stroke, and MI vs those with diabetes and MI in the health examination cohort. The trend of increasing HRs for all-cause mortality according to disease status was similarly observed in both male (Supplemental Table 1 ) and female (Supplemental Table 2 ) participants. Abbreviations: SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol. a P-value was estimated using x 2 tests for categorical variables and one-way analysis of variance for continuous variables.
b The denominators used to calculate the percentages are in row 2 of this table.
c P-value was estimated using Mantel-Haenszel tests for linear associations.
d ICD-10 codes used to define hypertension, dyslipidemia, and chronic kidney disease were I10, E78, and N18-9, respectively. f Heavy drinker was defined as consuming seven or more drinks on the same occasion more than 3 d/wk.
g Moderate physical activity was defined as more than five times per week.
h Tukey honest significant difference (HSD) test for posthoc pairwise comparison revealed significant differences between groups (none vs. diabetes, P-value , 0.0001; none vs. diabetes and stroke, P-value , 0.0001; none vs. diabetes and MI, P-value , 0.0001; diabetes vs. diabetes and stroke P-value = 0.015). i Tukey HSD test for posthoc pairwise comparison revealed significant differences between groups (none vs. diabetes, P-value , 0.0001).
j Calculated as weight in kilograms divided by height in meters squared. Outliers were excluded from the analysis.
k Tukey HSD test for post hoc pairwise comparison revealed significant differences between groups (none vs diabetes, P , 0.0001; none vs diabetes and MI, P = 0.040).
Estimates of life-years lost associated with diabetes A life table was constructed using calculations to estimate the life expectancy of our whole cohort (Supplemental Table 3 ). Using these results, the age-specific absolute differences in life expectancies of our cohort population according to cardiometabolic comorbidities were obtained (Supplemental Tables 4 and 5 ). The years of life lost by disease status of the cohort participants at baseline, compared with the reference group, are illustrated in Fig. 3(a) . Generally, the difference in life expectancy in each age group increased with an increasing number of cardiometabolic comorbidities accompanied, compared with those in the reference group [ Fig. 3(a) ]. In addition, the difference in life expectancy was the highest in the youngest age group and declined with increasing age across all cardiometabolic categories [ Fig. 3(a) ; Supplemental Table 4 ). For example, the difference in life expectancy was 23.79 in participants with diabetes, stroke, and MI and continually decreased to 8.71 in those between 75 and 79 years of age [ Fig. 3(a) ; Supplemental Table 4 ).
When we used the 2002 National Life Table data as the reference group, similar patterns in life expectancy of each age group according to the increasing number of cardiometabolic comorbidities and associated estimates of life-years lost across age groups were observed [ Fig.  3(b) ; Supplemental Table 5 ).
Contribution of age to the loss of life expectancy associated with diabetes
As shown in Table 3 , the overall life-years lost to diabetes in our whole cohort were 6.10 compared with those without diabetes. Compared with the reference group, the estimated life-years lost were 16.68 in those with a history of both diabetes and stroke, 21.10 in those with diabetes and MI, and 23.80 in those with all three conditions ( Table 3 ). The maximum contribution of age to the reduction of life expectancy was observed in younger age groups, which peaked at 45 to 49 years of age (12.04%) in participants with a history of diabetes; 40 to 44 years (33.17%) in those with a history of both diabetes and stroke, 35 to 39 years (33.65%) in those with diabetes and MI, and 45 to 49 years (36.79%) in those with all three conditions ( Table 3 ). The years and contributions of age to life expectancy were significantly reduced in subjects older than 60 years of age (Table 3) .
Discussion
This large, population-based, retrospective cohort study revealed the risk of mortality and estimates of age-specific reductions in life expectancy associated with different combinations of cardiometabolic morbidity (i.e., a history of diabetes, stroke, and MI). As expected, individuals with diabetes showed an approximate 70% increased relative risk of mortality compared with those without diabetes ( Table 2 ). The mortality rates and the age, sex, and other covariates adjusted HRs for mortality further increased significantly with an additional history of MI or stroke, or both. For instance, participants with only one of the studied conditions had an HR for mortality of about 1.7; for the combination of diabetes and one cardiovascular comorbidity (i.e., stroke or MI), the HR was about 3.5; and for a combination of all three conditions, the risk of death reaches approximately five-fold b HRs were calculated using Cox proportional hazards regression models adjusted for age (per 5-year interval), sex, hypertension, dyslipidemia, and chronic kidney disease at baseline in whole cohort. c HRs were calculated using Cox proportional hazards regression models adjusted for age (per 5-year interval), sex, hypertension, dyslipidemia, chronic kidney disease, BMI, smoking and drinking habits, and physical activity at baseline in health examination cohort. There were missing values in BMI (0.08%). We applied a multiple imputation procedure using a Markov Chain Monte Carlo method to impute missing values of BMI. The multiply imputed data sets were analyzed by the same analytical procedures, and the results from these analyses were combined to obtain an overall estimate.
( Table 2 ). This trend remained consistent in both the health examination cohort analysis (Table 2) and sexspecific analysis (Supplemental Tables 1 and 2 ). The increasing pattern of mortality risk with increasing cardiometabolic multimorbidity was also reported in a previous study that used data from the Emerging Risk Factors Collaboration and the UK Biobank (17) . In this study, the HRs of all-cause mortality were ;2, 4, and 8 in those patients who had combinations of one, two, or three cardiometabolic morbidities, respectively (17) . Similarly, another study using data from the Framingham Heart Study showed that people with diabetes and CVD had a significantly higher HR for mortality compared with those with diabetes but without CVD (18) , thereby highlighting the negative, additive, and nonoverlapping effects exerted by the combination of diabetes and CVD.
Multiple studies have reported higher excess mortality attributable to type 2 diabetes in those younger than age 55 years compared with older people (2, 10, 19) . Also, a recent study estimating the cumulative survival of people according to their cardiometabolic multimorbidity observed the maximum years of life lost to diabetes in their youngest age group (i.e., age 40 through 49 years) and its gradually attenuating tendency with increasing age (17) . Likewise, in our study, the age-specific contributions to life expectancy were generally highest in the younger age groups (except a few outliers due to a small number of subjects) and attenuated with increasing age, regardless of disease status (Table 3 ). In line with previous findings Figure 2 . Survival curves (a) in the whole cohort and (b) in the health examination cohort. Log-rank tests revealed P , 0.001 for all comparisons except the comparisons between subjects with diabetes and stroke vs those with diabetes and MI in both cohorts (P = 0.887 and 0.587, respectively) and between subjects with diabetes, stroke, and MI vs those with diabetes and MI in the health examination cohort (P = 0.074). Tables for Korea. (2, 10, 17, 19), our study results strongly suggest that young diabetic individuals, especially those with cardiovascular comorbidities, are much more likely to have their lifespan shortened compared with their counterparts who do not have diabetes and are older.
In general, the overall and age-specific reductions in life expectancy observed in our study are slightly less than those reported in previous studies of other ethnic populations. For instance, the overall life-years lost to diabetes were 6.10 in our cohort (Table 3) , whereas it was ;7.8 to 8.4 in a study that used the Framingham Heart study data (18) . Also, a large study of the noninstitutionalized US population showed a median reduced life expectancy of 8 years in the diabetic population 55 to 64 years old, and a 4-year reduction in the diabetic population 65 to 74 years old (19) . Another study using US NHIS data found diabetes decreased life years by 3.30 to 18.74 years depending on age, sex, and race (20) . In contrast, the lost years of life expectancy in our cohort were ;3 years for those 55 to 64 years of age and ;2 years for those 65 to 74 years of age [ Fig. 3(a) ; Supplemental Table 4 ), which were much less than those reported in the aforementioned studies of Western populations (19, 20) . These differences in life expectancy could be caused by multiple factors. First, some of these studies (18, 19) were conducted in the time during which treatment with statins, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and antiplatelet agents was much less common practice (21) . Therefore, our study, with a more recent dataset, could have led to more favorable results. Second, many of these studies did not subcategorize diabetic subjects according to the presence of cardiovascular comorbidity and its types (18) (19) (20) . Thus, the additive and malicious effects caused by the combination of diabetes and cardiovascular complications could have been mixed into the single category of "having diabetes." However, a few recent studies that considered cardiovascular comorbidity in their analyses also observed greater losses of life-years to cardiometabolic multimorbidity in a stepwise manner (17, 18) , implying that subject categorization is not a major contributor to this difference.
Last, it is plausible that ethnic differences could have resulted in the more favorable life expectancy in our study, as suggested by previous studies (20, 22) . It is well known that the pathophysiology and epidemiology of Asian type 2 diabetes differs from those in Western populations (4, 5, 23, 24) . For instance, the high proportion of body fat and prominent abdominal obesity in Asian people compared with those of European origin with similar BMI levels reflect a higher predisposition to insulin resistance at a lesser degree of obesity compared with people of European descent (25, 26) . Moreover, Asian people exhibit an earlier onset of impaired insulin secretion (25, 26) . These ethnic differences in the pathophysiology of diabetes may be responsible for the development of type 2 diabetes in Asian populations in a much shorter time, in a younger age group, and in people with much lower BMI (4). Therefore, it is possible that treatment with lifestyle modification and medication at younger ages before the development of macrovascular disease may have slowed the progression of atherosclerosis and lowered the risk of cardiovascular death in Asian people with type 2 diabetes (22) .
Our study has several strengths that make it different from previous studies. First, to our knowledge, this was the first study to evaluate and observe the reduced life expectancy among Asians with diabetes compared with people without such conditions. In a few previous studies that investigated the ethnic differences within a single country, white and black races were the majority of the study populations; people with Korean or East Asian backgrounds were categorized as "Others," along with people from other various Asian backgrounds. However, because the characteristics of type 2 diabetes may vary even within Asian countries (4), the ethnic differences found in the aforementioned studies (20, 22) could not have been generalized to East Asian populations. Second, detailed categorization of our cohort population using different combinations of CVD enabled us to delineate the additive effect of cardiovascular multimorbidity on mortality and life expectancy. Third, we have calculated and shown the age-specific contribution to the shortening of life expectancy in our cohort ( Table 3 ), suggesting that not only the age at diagnosis but also the current age of an individual with diabetes can be a risk determinant in predicting the loss of life expectancy. Last, this study used a large and national sample of patients with diabetes that allowed for a comprehensive understanding and ascertainment of information on mortality and life expectancy. Despite these strengths, our study has several limitations. First, our study only included people with type 2 diabetes and, hence, did not reflect information on mortality and life expectancy in people with type 1 diabetes in Korea. However, a much greater proportion of the diabetic population is diagnosed with type 2 diabetes in Korea (27) ; thus, we believe that our results are applicable to the majority of the Korean diabetic population. Second, because we defined type 2 diabetes, stroke, MI, and other covariates based on the presence of ICD-10 codes (and the prescription records of antidiabetic drugs when defining type 2 diabetes), it might have under-or overestimated the actual number of aforementioned conditions. Last, we did not have a sufficient number of participants younger than 45 years. Hence, the absolute differences in life expectancy in the category of participants with diabetes, stroke, and MI could not be calculated (Table 3) . Similarly, because information on other covariates, such as lifestyle habits and BMI, could not be obtained in the whole cohort, the mortality risk according to the cardiovascular multimorbidity might not represent the actual risk, as is the case with all epidemiological studies.
In conclusion, for the first time in Asia, to our knowledge, we observed the additive mortality risk and significantly shorter age-specific life expectancy in people with type 2 diabetes, depending on the number of cardiometabolic morbidities. Younger people, especially those with multimorbidity, lost a substantial amount of their life-years to diabetes compared with those without diabetes, stroke, and MI, despite being of the same age. Although the extent of the mortality risk and loss of life expectancy was less than that in Western studies, our results suggest that young Asians with diabetes should be followed and managed more stringently according to their cardiovascular comorbidities.
